The use of high-dose Ig formulations for the treatment of autoimmune diseases and inflammatory diseases suggests that the therapeutic potential of Igs may extend beyond their traditional use in immunodeficiency disorders. This evidence concerns the gene CUBN and immunodeficiency disease.